Palleschi, Michela
Prochowski Iamurri, Andrea
Scarpi, Emanuela
Mariotti, Marita
Maltoni, Roberta
Mannozzi, Francesca
Barone, Domenico
Paganelli, Giovanni
Casi, Michela
Giampalma, Emanuela
De Giorgi, Ugo
Rocca, Andrea
Article History
Received: 26 April 2021
Accepted: 8 February 2022
First Online: 1 March 2022
Competing interests
: This research received no external funding. Michela Palleschi has received advisory board fees from Novartis. Andrea Rocca has received travel grants and advisory board fees from Novartis, Roche, and Lilly. Ugo De Giorgi has received advisory board or consultant fees from Merck Sharp & Dohme, Bristol Myers Squibb, Janssen, Astellas, Sanofi, Bayer, Pfizer, Ipsen, Novartis, and Pharmamar and institutional research grants from Astrazeneca, Sanofi, and Roche. Giovanni Paganelli unpaid consultant for AAA. Remaining authors do not have competing interest.